Dr. Noah Biotech (닥터노아바이오텍)

Suwon, South Korea

DR.NOAH Biotech is the next-generation pharmaceutical company that seeks efficient new drug development based on big data analysis medicine and artificial intelligence technology. Based on the world's best drug forecasting technology, the company aims to develop the world's first treatment for rare genetic diseases. The new Orphan Drug Market is a growing market and an area of high investment value. There are more than 7,000 rare diseases, but more than 90 percent of them do not have proper drugs yet. It would take more than 500 years to develop the new drug at the current rate of development for the rare disease. DR.NOAH Biotech will be able to complete the prediction of orphan drug within 3 months by utilizing the technology to complete the development of the medication in a short time more efficiently than the conventional method.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Dr. Noah Biotech (닥터노아바이오텍) on @MedStartr Today #Biotech #MedMo #MedStartrVentures

https://www.medstartr.ai/s/i47XtRPOEjI

Get Involved in Dr. Noah Biotech (닥터노아바이오텍)

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2016
Website: www.drnoahbiotech.com/

Technologies

Biotechnology

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Dr. Noah Biotech (닥터노아바이오텍)?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.